Article

Design and synthesis of 4-[3,5-dioxo-11-oxa-4,9-diazatricyclo[5.3.1.0(2,6)]undec-4-yl]-2-trifluoromethyl-benzonitriles as androgen receptor antagonists.

Bristol-Myers Squibb Company, Research and Development, Princeton, NJ 08543-4000, USA.
Bioorganic & medicinal chemistry letters (impact factor: 2.65). 08/2010; 20(15):4491-5. DOI:10.1016/j.bmcl.2010.06.034 pp.4491-5
Source: PubMed

ABSTRACT A novel series of 4-[3,5-dioxo-11-oxa-4,9-diazatricyclo[5.3.1.0(2,6)]undec-4-yl]-2-trifluoromethyl-benzonitriles has been synthesized. The ability of these compounds to act as antagonists of the androgen receptor was investigated and several were found to have potent activity in vitro and in vivo.

0 0
 · 
0 Bookmarks
 · 
94 Views
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.

Keywords

compounds
 
novel series
 
potent activity
 
vivo